Evidence map›Paper›PMID 21998588›Full record

ArticlePLoS pathogens2011

The anti-interferon activity of conserved viral dUTPase ORF54 is essential for an effective MHV-68 infection.

Ronika Sitapara Leang, Ting-Ting Wu, Seungmin Hwang, Lidia T Liang, Leming Tong, Jennifer T Truong, Ren Sun

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Is dUTPase Enzymatic Activity Truly Essential for Viability?International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Regulation of cGAS-Mediated Immune Responses and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ronika Sitapara LeangMolecular Biology Institute, University of California Los Angeles, Los Angeles, California, United States of America.
Ting-Ting Wu
Seungmin Hwang
Lidia T Liang
Leming Tong
Jennifer T Truong
Ren Sun
University of California, Los Angeles · US

Funding

UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
ORF36 Viral Kinase as a Transcriptional Regulator of KSHVP01DE019085 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SUN, REN · 2008 to 2012
$6.4M
Immunogenicity and efficacy of genetically engineered gamma-herpesvirus vaccinesRC2CA148250 · NCI · TRUDEAU INSTITUTE, INC. · PI BLACKMAN, MARCIA A, SUN, REN · 2009 to 2010
$1000k
Genetic Analysis of Interactions Between Oral Innate Immunity and a HerpesvirusR21DE018337 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, TING-TING · 2007 to 2008
$421k
NCI NIH HHS RC2 CA148250NCI NIH HHS RC2CA148250NIDCR NIH HHS P01 DE019085NIDCR NIH HHS P01DE019085NIDCR NIH HHS R21 DE018337NIDCR NIH HHS R21DE18337NIGMS NIH HHS GM007185NIGMS NIH HHS T32 GM007185
6 · The paper itself

Abstract

Gammaherpesviruses such as KSHV and EBV establish lifelong persistent infections through latency in lymphocytes. These viruses have evolved several strategies to counteract the various components of the innate and adaptive immune systems. We conducted an unbiased screen using the genetically and biologically related virus, MHV-68, to find viral ORFs involved in the inhibition of type I interferon signaling and identified a conserved viral dUTPase, ORF54. Here we define the contribution of ORF54 in type I interferon inhibition by ectopic expression and through the use of genetically modified MHV-68. ORF54 and an ORF54 lacking dUTPase enzymatic activity efficiently inhibit type I interferon signaling by inducing the degradation of the type I interferon receptor protein IFNAR1. Subsequently, we show in vitro that the lack of ORF54 causes a reduction in lytic replication in the presence of type I interferon signaling. Investigation of the physiological consequence of IFNAR1 degradation and importance of ORF54 during MHV-68 in vivo infection demonstrates that ORF54 has an even greater impact on persistent infection than on lytic replication. MHV-68 lacking ORF54 expression is unable to efficiently establish latent infection in lymphocytes, although it replicates relatively normally in lung tissues. However, infection of IFNAR-/- mice alleviates this phenotype, emphasizing the specific role of ORF54 in type I interferon inhibition. Infection of mice and cells by a recombinant MHV-68 virus harboring a site specific mutation in ORF54 rendering the dUTPase inactive demonstrates that dUTPase enzymatic activity is not required for anti-interferon function of ORF54. Moreover, we find that dUTPase activity is dispensable at all stages of MHV-68 infection analyzed. Overall, our data suggest that ORF54 has evolved anti-interferon activity in addition to its dUTPase enzymatic activity, and that it is actually the anti-interferon role that renders ORF54 critical for establishing an effective persistent infection of MHV-68.

Indexed as

AnimalsChlorocebus aethiopsGene Expression Regulation, ViralGenes, ViralHerpesviridae InfectionsHumansImmunity, InnateInterferon Type IMiceMice, KnockoutModels, AnimalNIH 3T3 CellsPlasmidsPyrophosphatasesReceptor, Interferon alpha-betaRecombination, GeneticdUTP pyrophosphataseInterferon Type IPyrophosphatasesReceptor, Interferon alpha-betaViral Proteins

Identifiers

PMID21998588
PMCPMC3188543
OpenAlexW2084268304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.